Evidence map›Paper›PMID 31439004›Full record

ArticleTrials2019

VIBRA trial - Effect of village-based refill of ART following home-based same-day ART initiation vs clinic-based ART refill on viral suppression among individuals living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho.

Alain Amstutz, Thabo Ishmael Lejone, Lefu Khesa, Josephine Muhairwe, Bienvenu Lengo Nsakala, Katleho Tlali, Moniek Bresser, Fabrizio Tediosi, Mathebe Kopo, Mpho Kao and 4 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03630549 (Village-based Refill of ART After Same-day ART Start vs Clinic-based ART Refill for HIV-positive Individuals Not on ART During Home-based HIV Testing), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03630549 phase4completednot on this map

Village-based Refill of ART After Same-day ART Start vs Clinic-based ART Refill for HIV-positive Individuals Not on ART During Home-based HIV Testing (Part B of GET ON Research Project)

TypeinterventionalSponsorNiklaus LabhardtRan2018 to 2020Enrolled257ConditionsHIV/AIDSArmsStandard of Care, Village-based ART refill
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Necessary but Not Sufficient: The Need for Innovative Strategies to Enhance Retention and Viral Suppression After Rapid Initiation of Antiretroviral Therapy.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alain AmstutzClinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051, Basel, Switzerland.
Thabo Ishmael LejoneSolidarMed, Swiss Organization for Health in Africa, Butha-Buthe, Lesotho.
Lefu KhesaSolidarMed, Swiss Organization for Health in Africa, Butha-Buthe, Lesotho.
Josephine MuhairweSolidarMed, Swiss Organization for Health in Africa, Butha-Buthe, Lesotho.
Bienvenu Lengo NsakalaSolidarMed, Swiss Organization for Health in Africa, Butha-Buthe, Lesotho.
Katleho TlaliSolidarMed, Swiss Organization for Health in Africa, Butha-Buthe, Lesotho.
Moniek BresserClinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051, Basel, Switzerland.
Fabrizio TediosiClinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051, Basel, Switzerland.
Mathebe KopoSolidarMed, Swiss Organization for Health in Africa, Butha-Buthe, Lesotho.
Mpho KaoSolidarMed, Swiss Organization for Health in Africa, Butha-Buthe, Lesotho.
Thomas KlimkaitUniversity of Basel, 4051, Basel, Switzerland.
Manuel BattegayUniversity of Basel, 4051, Basel, Switzerland.
Tracy Renée GlassClinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051, Basel, Switzerland.
Niklaus Daniel LabhardtClinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051, Basel, Switzerland. n.labhardt@swisstph.ch.ORCID http://orcid.org/0000-0003-3599-1791

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 323530_177576Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung IZ07Z0_160876/1Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung PCEFP3_181355Stiftung Infektiologie beider Basel N/A
6 · The paper itself

Abstract

backgroundThere is a need for evaluating community-based antiretroviral therapy (ART) delivery models to improve overall performance of HIV programs, specifically in populations that may have difficulties to access continuous care. This cluster-randomized clinical trial aims to evaluate the effectiveness of a multicomponent differentiated ART delivery model (VIBRA model) after home-based same-day ART initiation in remote villages in Lesotho, southern Africa. METHODS/

designThe VIBRA trial (VIllage-Based Refill of ART) is a cluster-randomized parallel-group superiority clinical trial conducted in two districts in Lesotho, southern Africa. Clusters (i.e., villages) are randomly assigned to either the VIBRA model or standard care. The clusters are stratified by district, village size, and village access to the nearest health facility. Eligible individuals (HIV-positive, aged 10 years or older, and not taking ART) identified during community-based HIV testing campaigns are offered same-day home-based ART initiation. The intervention clusters offer a differentiated ART delivery package with two features: (1) drug refills and follow-ups by trained and supervised village health workers (VHWs) and (2) the option of receiving individually tailored adherence reminders and notifications of viral load results via SMS. The control clusters will continue to receive standard care, i.e., collecting ART refills from a clinic and no SMS notifications. The primary endpoint is viral suppression 12 months after enrolment. Secondary endpoints include linkage to and engagement in care. Furthermore, safety and cost-effectiveness analyses plus qualitative research are planned. The minimum target sample size is 262 participants. The statistical analyses will follow the CONSORT guidelines. The VIBRA trial is linked to another trial, the HOSENG (HOme-based SElf-testiNG) trial, both of which are within the GET ON (GETing tOwards Ninety) research project. DISCUSSION: The VIBRA trial is among the first to evaluate the delivery of ART by VHWs immediately after ART initiation. It assesses the entire HIV care cascade from testing to viral suppression. As most countries in sub-Saharan Africa have cadres like the VHW program in Lesotho, this model-if shown to be effective-has the potential to be scaled up. The system impact evaluation will provide valuable cost estimations, and the qualitative research will suggest how the model could be further modified to optimize its impact.

trial registrationClinicaltrials.gov, NCT03630549 . Registered on 15 August 2018.

Indexed as

Medication AdherenceAnti-HIV AgentsDelivery of Health CareDrug PrescriptionsEquivalence Trials as TopicHIVHIV InfectionsHumansLesothoMulticenter Studies as TopicRural Health ServicesTime FactorsTreatment OutcomeViral LoadAnti-HIV Agentsantiretroviral therapycluster randomized controlled trialcommunity health workerdifferentiated care and deliveryHIVhome-basedLesothomulti component interventionSouthern Africavillage health worker

Identifiers

PMID31439004
PMCPMC6704675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.